Applied DNA Sciences, Inc. (APDN)
USD 0.23
(1.26%)
USD 0.23
(1.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.48 Million USD | -13.33% |
| 2022 | 19.02 Million USD | 10.47% |
| 2021 | 17.22 Million USD | 25.28% |
| 2020 | 13.74 Million USD | 0.81% |
| 2019 | 13.63 Million USD | -4.93% |
| 2018 | 14.34 Million USD | -13.04% |
| 2017 | 16.49 Million USD | 5.46% |
| 2016 | 15.63 Million USD | -7.25% |
| 2015 | 16.86 Million USD | 12.47% |
| 2014 | 14.99 Million USD | 22.77% |
| 2013 | 12.21 Million USD | 46.04% |
| 2012 | 8.36 Million USD | -7.35% |
| 2011 | 9.02 Million USD | 19.16% |
| 2010 | 7.57 Million USD | 6.23% |
| 2009 | 7.12 Million USD | 46.79% |
| 2008 | 4.85 Million USD | -61.57% |
| 2007 | 12.63 Million USD | -19.54% |
| 2006 | 15.7 Million USD | -64.02% |
| 2005 | 43.65 Million USD | 148.29% |
| 2004 | 17.58 Million USD | 406.96% |
| 2003 | 3.46 Million USD | 40314.39% |
| 2002 | 8582.00 USD | 50.03% |
| 2001 | 5720.00 USD | 70.54% |
| 2000 | 3354.00 USD | 112.01% |
| 1999 | 1582.00 USD | 149.53% |
| 1998 | 634.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.72 Million USD | -7.29% |
| 2024 Q1 | 4.02 Million USD | -5.4% |
| 2024 Q3 | 3.45 Million USD | -3.63% |
| 2023 Q1 | 3.59 Million USD | -24.85% |
| 2023 FY | 16.48 Million USD | -13.33% |
| 2023 Q3 | 4.12 Million USD | -8.49% |
| 2023 Q2 | 4.51 Million USD | 25.43% |
| 2023 Q4 | 4.24 Million USD | 2.94% |
| 2022 Q2 | 4.48 Million USD | -21.93% |
| 2022 Q3 | 3.87 Million USD | -13.51% |
| 2022 Q1 | 5.74 Million USD | 54.14% |
| 2022 FY | 19.02 Million USD | 10.47% |
| 2022 Q4 | 4.78 Million USD | 23.45% |
| 2021 FY | 17.22 Million USD | 25.28% |
| 2021 Q1 | 4.34 Million USD | 3.2% |
| 2021 Q2 | 4.63 Million USD | 6.54% |
| 2021 Q3 | 4.51 Million USD | -2.45% |
| 2021 Q4 | 3.72 Million USD | -17.53% |
| 2020 Q2 | 3.05 Million USD | 1.4% |
| 2020 Q1 | 3.01 Million USD | -6.33% |
| 2020 FY | 13.74 Million USD | 0.81% |
| 2020 Q4 | 4.21 Million USD | 21.54% |
| 2020 Q3 | 3.46 Million USD | 13.43% |
| 2019 FY | 13.63 Million USD | -4.93% |
| 2019 Q3 | 3.21 Million USD | -1.95% |
| 2019 Q4 | 3.21 Million USD | 0.07% |
| 2019 Q1 | 3.92 Million USD | -10.95% |
| 2019 Q2 | 3.27 Million USD | -16.53% |
| 2018 Q2 | 2.81 Million USD | -19.46% |
| 2018 Q3 | 3.63 Million USD | 29.11% |
| 2018 Q4 | 4.41 Million USD | 21.49% |
| 2018 Q1 | 3.49 Million USD | -6.05% |
| 2018 FY | 14.34 Million USD | -13.04% |
| 2017 Q4 | 3.71 Million USD | -10.84% |
| 2017 FY | 16.49 Million USD | 5.46% |
| 2017 Q3 | 4.16 Million USD | 3.42% |
| 2017 Q2 | 4.02 Million USD | -12.05% |
| 2017 Q1 | 4.58 Million USD | 27.13% |
| 2016 Q1 | 4.24 Million USD | -5.0% |
| 2016 FY | 15.63 Million USD | -7.25% |
| 2016 Q2 | 4.02 Million USD | -5.28% |
| 2016 Q3 | 3.95 Million USD | -1.66% |
| 2016 Q4 | 3.6 Million USD | -8.85% |
| 2015 Q3 | 3.93 Million USD | 15.96% |
| 2015 Q4 | 4.46 Million USD | 13.41% |
| 2015 FY | 16.86 Million USD | 12.47% |
| 2015 Q2 | 3.39 Million USD | -32.85% |
| 2015 Q1 | 5.05 Million USD | 45.04% |
| 2014 Q4 | 3.48 Million USD | 4.81% |
| 2014 FY | 14.99 Million USD | 22.77% |
| 2014 Q1 | 4.41 Million USD | 43.12% |
| 2014 Q2 | 3.76 Million USD | -14.64% |
| 2014 Q3 | 3.32 Million USD | -11.59% |
| 2013 FY | 12.21 Million USD | 46.04% |
| 2013 Q1 | 2.68 Million USD | 30.71% |
| 2013 Q2 | 2.95 Million USD | 9.77% |
| 2013 Q4 | 3.08 Million USD | -11.66% |
| 2013 Q3 | 3.48 Million USD | 18.13% |
| 2012 FY | 8.36 Million USD | -7.35% |
| 2012 Q4 | 2.05 Million USD | 5.22% |
| 2012 Q3 | 1.95 Million USD | -3.15% |
| 2012 Q2 | 2.01 Million USD | -13.3% |
| 2012 Q1 | 2.32 Million USD | -42.6% |
| 2011 Q3 | 1.72 Million USD | -3.88% |
| 2011 Q4 | 4.05 Million USD | 135.82% |
| 2011 FY | 9.02 Million USD | 19.16% |
| 2011 Q1 | 1.42 Million USD | -26.5% |
| 2011 Q2 | 1.79 Million USD | 25.84% |
| 2010 FY | 7.57 Million USD | 6.23% |
| 2010 Q1 | 1.64 Million USD | 31.51% |
| 2010 Q2 | 1.37 Million USD | -16.2% |
| 2010 Q4 | 1.93 Million USD | -26.16% |
| 2010 Q3 | 2.62 Million USD | 90.51% |
| 2009 Q2 | 1.83 Million USD | -37.66% |
| 2009 Q1 | 2.93 Million USD | 178.27% |
| 2009 Q4 | 1.24 Million USD | 11.85% |
| 2009 FY | 7.12 Million USD | 46.79% |
| 2009 Q3 | 1.11 Million USD | -39.01% |
| 2008 Q4 | 1.05 Million USD | -2.43% |
| 2008 Q3 | 1.08 Million USD | 0.0% |
| 2008 Q2 | 1.08 Million USD | -41.32% |
| 2008 Q1 | 1.84 Million USD | -70.33% |
| 2008 FY | 4.85 Million USD | -61.57% |
| 2007 FY | 12.63 Million USD | -19.54% |
| 2007 Q4 | 6.2 Million USD | 195.31% |
| 2007 Q3 | 2.1 Million USD | -1.6% |
| 2007 Q2 | 2.13 Million USD | -2.5% |
| 2007 Q1 | 2.19 Million USD | -77.31% |
| 2006 Q1 | 2.43 Million USD | -88.42% |
| 2006 Q4 | 9.65 Million USD | 532.11% |
| 2006 Q3 | 1.52 Million USD | 7.09% |
| 2006 Q2 | 1.42 Million USD | -41.48% |
| 2006 FY | 15.7 Million USD | -64.02% |
| 2005 Q3 | 2.75 Million USD | -55.31% |
| 2005 Q1 | 10.79 Million USD | 63.78% |
| 2005 Q2 | 6.15 Million USD | -42.98% |
| 2005 FY | 43.65 Million USD | 148.29% |
| 2005 Q4 | 21.05 Million USD | 665.31% |
| 2004 Q2 | 1.9 Million USD | -74.22% |
| 2004 Q1 | 7.4 Million USD | 68.7% |
| 2004 Q3 | 1.67 Million USD | -12.4% |
| 2004 Q4 | 6.59 Million USD | 294.12% |
| 2004 FY | 17.58 Million USD | 406.96% |
| 2003 Q1 | 147.19 Thousand USD | 0.0% |
| 2003 Q3 | 325.88 Thousand USD | -24.74% |
| 2003 Q4 | 4.39 Million USD | 1247.5% |
| 2003 FY | 3.46 Million USD | 40314.39% |
| 2003 Q2 | 432.98 Thousand USD | 194.16% |
| 2002 Q1 | 210.00 USD | -97.43% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 FY | 8582.00 USD | 50.03% |
| 2001 Q3 | 105.00 USD | 0.0% |
| 2001 Q1 | 5159.00 USD | 2766.11% |
| 2001 FY | 5720.00 USD | 70.54% |
| 2001 Q4 | 8162.00 USD | 7673.33% |
| 2001 Q2 | 105.00 USD | -97.96% |
| 2000 Q4 | 180.00 USD | 13.21% |
| 2000 FY | 3354.00 USD | 112.01% |
| 2000 Q2 | 222.00 USD | -92.69% |
| 2000 Q3 | 159.00 USD | -28.38% |
| 2000 Q1 | 3037.00 USD | 0.0% |
| 1999 Q2 | 159.00 USD | 0.0% |
| 1999 Q3 | 158.00 USD | -0.63% |
| 1999 Q4 | - USD | -100.0% |
| 1999 FY | 1582.00 USD | 149.53% |
| 1998 FY | 634.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 88.935% |
| Prenetics Global Limited | 60.73 Million USD | 72.855% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1.32% |
| CareDx, Inc | 277.76 Million USD | 94.065% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.2% |
| Exagen Inc. | 52.29 Million USD | 68.472% |
| Inotiv, Inc. | 246.9 Million USD | 93.323% |
| Guardant Health, Inc. | 901.62 Million USD | 98.171% |
| Biodesix, Inc. | 77.41 Million USD | 78.705% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -320.249% |
| Precipio, Inc. | 13.63 Million USD | -20.888% |
| iSpecimen Inc. | 16.27 Million USD | -1.287% |
| Natera, Inc. | 938.98 Million USD | 98.244% |
| Aspira Women's Health Inc. | 24.11 Million USD | 31.63% |
| Standard BioTools Inc. | 113.48 Million USD | 85.473% |
| 23andMe Holding Co. | 420.73 Million USD | 96.081% |
| Castle Biosciences, Inc. | 242.78 Million USD | 93.209% |
| Personalis, Inc. | 128.14 Million USD | 87.134% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 85.083% |
| OpGen, Inc. | 30.65 Million USD | 46.224% |
| T2 Biosystems, Inc. | 41.49 Million USD | 60.267% |
| Myriad Genetics, Inc. | 600.1 Million USD | 97.253% |
| ICON Public Limited Company | 755.64 Million USD | 97.818% |
| NeoGenomics, Inc. | 341.25 Million USD | 95.169% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1.32% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.491% |
| RadNet, Inc. | 268.87 Million USD | 93.868% |
| MDxHealth SA | 71.25 Million USD | 76.863% |
| Psychemedics Corporation | 11.33 Million USD | -45.463% |
| Illumina, Inc. | 3.81 Billion USD | 99.568% |
| Check-Cap Ltd. | 19.28 Million USD | 14.519% |
| Twist Bioscience Corporation | 354.18 Million USD | 95.345% |
| DarioHealth Corp. | 62.17 Million USD | 73.483% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 90.409% |
| Sera Prognostics, Inc. | 39.91 Million USD | 58.697% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -56.707% |
| OPKO Health, Inc. | 574.68 Million USD | 97.131% |
| Medpace Holdings, Inc. | 187.68 Million USD | 91.216% |
| Neogen Corporation | 405.23 Million USD | 95.932% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -40.806% |
| Prenetics Global Limited | 60.73 Million USD | 72.855% |
| Mainz Biomed B.V. | 27.15 Million USD | 39.285% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -88.101% |
| Trinity Biotech plc | 46.49 Million USD | 64.541% |
| Neuronetics, Inc. | 82.25 Million USD | 79.958% |
| Sotera Health Company | 300.46 Million USD | 94.513% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -88.101% |